BiotechTube

IMP321 (eftilagimod alpha) + Placebo + Paclitaxel

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Adenocarcinoma Breast Stage IV

Conditions

Adenocarcinoma Breast Stage IV

Trial Timeline

Dec 1, 2015 → May 1, 2021

NCT ID
NCT02614833

About IMP321 (eftilagimod alpha) + Placebo + Paclitaxel

IMP321 (eftilagimod alpha) + Placebo + Paclitaxel is a phase 2 stage product being developed by Immutep for Adenocarcinoma Breast Stage IV. The current trial status is completed. This product is registered under clinical trial identifier NCT02614833. Target conditions include Adenocarcinoma Breast Stage IV.

What happened to similar drugs?

1 of 20 similar drugs in Adenocarcinoma Breast Stage IV were approved

Approved (1) Terminated (0) Active (19)
✅ApatinibTabletsJiangsu Hengrui MedicineApproved
🔄Ramucirumab + Paclitaxel + PlaceboEli LillyPhase 3
🔄CT-P16 + AvastinCelltrionPhase 3
🔄Bevacizumab + Capecitabine + Cisplatin + Placebo + 5-fluorouracilChugai PharmaceuticalPhase 3
🔄Trastuzumab deruxtecan + Ramucirumab + PaclitaxelDaiichi SankyoPhase 3
🔄zolbetuximab + placebo + oxaliplatin + folinic acid + fluorouracilAstellas PharmaPhase 3
🔄zolbetuximab + oxaliplatin + capecitabine + placeboAstellas PharmaPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02614833Phase 2Completed

Competing Products

20 competing products in Adenocarcinoma Breast Stage IV

See all competitors
ProductCompanyStageHype Score
CD40 agonist mitazalimab in combination with chemotherapyAlligator Bioscience ABPhase 1/2
26
Autologous Mesothelin-specific TCR-T Cells + Cyclophosphamide + Fludarabine + BendamustineLonzaPhase 1
18
[203Pb]Pb-PSV359 + [212Pb]Pb-PSV359Perspective TherapeuticsPhase 1/2
33
Zentalis + GemzarZentalis PharmaceuticalsPhase 2
29
ACR-368 + GemcitabineAcrivon TherapeuticsPhase 2
32
RamucirumabEli LillyPhase 1/2
32
Ramucirumab + Paclitaxel + PlaceboEli LillyPhase 3
40
BA3182BioAtlaPhase 1
26
Ramucirumab (IMC-1121B ) + PaclitaxelEli LillyPhase 1
29
CT-P16 + AvastinCelltrionPhase 3
40
Bevacizumab + Capecitabine + Cisplatin + Placebo + 5-fluorouracilChugai PharmaceuticalPhase 3
40
Trastuzumab DeruxtecanDaiichi SankyoPhase 2
35
Trastuzumab deruxtecan + Ramucirumab + PaclitaxelDaiichi SankyoPhase 3
44
Trastuzumab Deruxtecan (T-DXd) monotherapy + T-DXd, Durvalumab and Capecitabine CombinationDaiichi SankyoPhase 2
42
Trastuzumab deruxtecanDaiichi SankyoPhase 2
35
DS-8201aDaiichi SankyoPhase 1
29
Trastuzumab deruxtecan + 5FU/LV + Trastuzumab deruxtecan + FLODaiichi SankyoPhase 1/2
39
EnzalutamideAstellas PharmaPhase 2
35
zolbetuximabAstellas PharmaPre-clinical
30
zolbetuximab + placebo + oxaliplatin + folinic acid + fluorouracilAstellas PharmaPhase 3
44